The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Biohaven regarding the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback